Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 18976 | 10.0371 |
09:34 ET | 100 | 9.92 |
09:36 ET | 1046 | 9.88 |
09:38 ET | 3250 | 9.835 |
09:39 ET | 1700 | 9.8162 |
09:41 ET | 1000 | 9.82 |
09:45 ET | 2965 | 9.87 |
09:48 ET | 700 | 9.84 |
09:50 ET | 300 | 9.85 |
09:52 ET | 1220 | 9.82 |
09:54 ET | 1158 | 9.85 |
09:59 ET | 3241 | 9.89 |
10:01 ET | 1500 | 9.88 |
10:03 ET | 4508 | 9.83 |
10:06 ET | 1000 | 9.84 |
10:08 ET | 400 | 9.84 |
10:12 ET | 500 | 9.81 |
10:14 ET | 500 | 9.805 |
10:17 ET | 899 | 9.79 |
10:19 ET | 400 | 9.79 |
10:21 ET | 200 | 9.795 |
10:26 ET | 131 | 9.795 |
10:28 ET | 300 | 9.79 |
10:32 ET | 300 | 9.785 |
10:33 ET | 800 | 9.79 |
10:35 ET | 441 | 9.785 |
10:37 ET | 588 | 9.76 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.4B | -2.4x | --- |
Prothena Corporation PLC | 1.3B | -7.1x | --- |
Silence Therapeutics PLC | 1.1B | -14.3x | --- |
Immatics NV | 1.1B | -10.1x | --- |
Arcus Biosciences Inc | 1.6B | -5.6x | --- |
4D Molecular Therapeutics Inc | 1.3B | -10.5x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
---|---|
Revenue (TTM) | $79.6M |
Shares Outstanding | 136.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-4.01 |
Book Value | $11.80 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | 17.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -780.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.